{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 400,
  "pageCount": 415,
  "prevPage": 399,
  "nextPage": 401,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a combination of summary bullet points and verbatim Q&A transcripts to highlight the expert's negative assessment.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/400",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-400",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "it's not some world-changingly powerful medication.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c5-08f1cba3bf44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "list",
      "text": "Skeptical of Vykat – weak data; drug barely got FDA approval; failed trials, “not some world-changingly powerful medication”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79c0457b-f058-4b57-9875-3cdb07cfa3b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.44
      },
      "kind": "list",
      "text": "Clinical data is “underwhelming” esp the withdrawal study upon which FDA approval was based; skeptical of lack of hard endpoints one would expect vs. just a questionnaire",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f581e45-8fd2-4d2b-8212-4e956ed5f22c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "stating the studies were “a little underwhelming” and failed to show weight reduction or a proper endpoint – and that he wouldn’t push it patients: “if the goal here is largely appetite, weight, that sort of zone, at least show a benefit in BMI or something...those are the typical endpoints that we use...in this space”; “the data is not so strong with this medication that we're going to push hard”; “while the medicine is approved and there are not a lot of options in PWS, it's not like the data was like so strong...the drug had to fight hard to get approved...it failed at initial trial and had to get a second bite at the apple...it's not some world-changingly powerful medication.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9934ab89-c0ba-4d5b-af54-eb69e6c67873",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.85,
        "x": 0.07,
        "y": 0.72
      },
      "kind": "quote",
      "text": "Q: “Do you think PWS families in that second group, that's how they're relating to Vykat right now? Just kind of more wait-and-see. Is that your assessment?” A: “...so far, to be fair, the data is not so strong with this medication that we're going to push hard as far as that's concerned... And while the medicine is approved and there are not a lot of options in PWS, it's not like the data was like so strong. The drug had to fight hard to get approved. It tried a trial before, and it failed at initial trial and had to get a second bite at the apple and everything like that. It's not some world-changingly powerful medication.” - Endocrinologist in TX, private practice with 5 PWS patients",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "586c901b-fd5a-4d91-84d4-17b9d43624e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.07,
        "y": 0.51
      },
      "kind": "quote",
      "text": "Q: “The entire basis of FDA approval is a randomized withdrawal study, where the patients on placebo had a worsening on the dysphagia survey. And that's it, basically.” A: “That's exactly right. It's a little underwhelming... if the goal here is largely appetite, weight, that sort of zone, at least show a benefit in BMI or something. Those are the typical endpoints that we use when we talk about medicines in this space.” - Endocrinologist in TX, private practice with 5 PWS patients",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e14cad82-bbf5-4e15-99bc-91019e680772",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"That's exactly right. It's a little underwhelming. Your questionnaire result was better in one group versus another. But hard endpoint - heart attacks, strokes, deaths. Granted, that's a very high bar to meet. Very few drugs are going to be so powerful that you knock it out of the park that way. But, if the goal here is largely appetite, weight, that sort of zone, at least show a benefit in BMI or something. Those are the typical endpoints that we use when we talk about medicines in this space.\" — Endocrinologist in TX, private practice with 5 PWS patients",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c5-0ead1e9800e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aecaea47-8c08-4590-b50b-97bd851f897f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "The endocrinologist indicated extreme skepticism of Vykat on all counts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c36e1dd-7730-4063-92fd-a1c545a02e1e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}